Today, the Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis ...
Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.
Add Yahoo as a preferred source to see more of our stories on Google. Clinical Trials Arena presents the obesity highlights from ADA 2026 As the 2026 American Diabetes Association (ADA) conference ...
Obesity rates among U.S. adults and children rose sharply in recent years and by 2023, 40% of adults and 20% of youth met the ...
Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific societies. In practice, however, many women who decide to undergo ...
ADA 2026 GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D Patients with co-occurring obesity and T2D have more favorable QOL outcomes on GLP-1s than those with either condition alone or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results